Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia.
Clinical Trial # E1912:
Ibrutnib and Rituximab vs standard FCR to prolong progression free survival of Chronic Lympocytic Leukemia or Small Lymphocytic Leukemia.
Participants muse be 18-70 years of age with a performance status of 0-2. The diagnosis of Chronic Lympocytic Leukemia or Small Lymphocytic Leukemia must be according to NCI/WCLL or SLL according to WHO criteria.
Exclusions include but are not limited to: Prior chemotherapy or monoclonal antibody therapy, major surgery within 28 days of registration, radiation therapy < 4 weeks prior to registration, recent Myocardial Infarction or Cerebrovascula Accident.
“I have an aggressive type of cancer and it was time to take drastic measures…When I heard about the trial from Dr. Hodge, I felt privileged to have this type of care and the chance to help others who may be in my shoes one day.”